BioPharmSignal logoBioPharmSignal

Biotech News

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Instil Bio (TIL)Instil BioPartnership

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Related news

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIXNurix Therapeutics2026-06-08 05:00 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

REPLReplimune Group2026-06-26 12:00 EST

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

View all latest news

Instil Bio

Therapeutics Acquisition Strategy Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutics. It is evaluating acquisitions, in-licensing transactions, and related opportunities that could provide access to new drug candidates. Portfolio Rebuilding Following the wind-down of prior internal...

Recent company news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-05-15 11:00 EST

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-03-27 11:00 EST

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TILInstil Bio2026-01-06 12:00 EST

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

TILInstil Bio2025-11-13 12:00 EST

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
7.58 USD
Market cap
55M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States